Sarsia is an early-stage venture capital firm We invest in a greener and healthier future


Closeup of a woman looking through a microscope
Visit page


Bridge with sky as background
Visit page


Reliability is at the core of what we do

Visit page


Background in science, experience from industry

Sarsia strenght lies in our differences; people with diverse backgrounds, knowledge and experience giving different perspectives.

Visit page

Investment areas

  • Life Sciences

    Our focus is on unmet medical needs. Where competence and capital are decisive when turning a laboratory result into an effective treatment for the patient.

    Visit page
  • Technology, Energy and Sustainability

    We search for technologies and founders capable of accelerating the green transition and of building sustainable companies for the future.

    Visit page

A talent for value creation begins with the will to dare the unknown

Theories, hypotheses and research are rooted in ambition. Clear goals, systematic hard work and dedication create results. Sarsia focus on technologies that can improve the quality of life, society and reduce negative impact on nature. Sarsia creates value by linking good solutions and science with competent capital. We thrive on change, and dare to take risks to create value. This has made us one of the best performing VC firms in the Nordic countries.

  • 17
    Years since startup
  • 900
    mNOK (2 funds)
  • 12600
    mNOK Portfolio IPEV Value
  • 1140 companies screened

  • 29 portfolio companies

  • Top performance among Norwegian Early Stage Venture funds

  • Two of the most valuable early stage venture backed companies in Norway.

Latest news

  • Mon Jan 02 2023

    Coegin Pharma raises 25 mSEK

    Coegin Pharma AB (COEGIN:Nordic GM) raises 25,3 mSEK through combined rights issue and directed new

    Read full article
  • Fri Dec 16 2022

    Rallybio publishes promising results with technology aquired from Prophylix Pharma

    American biotech company Rallybio publishes proof-of-concept data from animal studies with technolog

    Read full article
  • Tue Dec 06 2022

    Nykode Therapeutics announces clinical collaboration with MSD

    Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination Wit

    Read full article